Smoking topography characteristics of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls

Nicotine and Tobacco Research

Volumn 18, Issue 9, 2016, Pages 1807-1812

  Tidey, Jennifer W ^a   Cassidy, Rachel N ^a   Miller, Mollie E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE PATCH; NICOTINE; NICOTINE GUM;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DSM-IV; FEASIBILITY STUDY; FEMALE; HEALTH CARE POLICY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; TOBACCO DEPENDENCE; VERY LOW NICOTINE CONTENT CIGARETTE; ADDICTION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; SMOKING CESSATION;

ADULT; BEHAVIOR, ADDICTIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS;

EID: 84988810633     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw089     Document Type: Article

References (43)

1. Dickerson F, Stallings CR, Origoni AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv. 2013;64(1):44-50. doi:10.1176/appi. ps.201200143.
2. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248-254. doi:10.1001/jamapsychiatry.2013.3726.
3. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States [published online ahead of print October 28, 2015]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2015.1737.
4. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol. 2009;5:409-431. doi:10.1146/annurev. clinpsy.032408.153614.
5. Steinberg ML, Williams JM, Gandhi KK, et al. Lower task persistence in smokers with schizophrenia as compared to non-psychiatric control smokers. Psychol Addict Behav. 2010;24(4):724-729. doi:10.1037/a0020972.
6. Tidey JW, Colby SM, Xavier EM. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine Tob Res. 2014;16(3):326-334. doi:10.1093/ntr/ntt152.
7. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311(2):145-154. doi:10.1001/jama.2013.285113.
8. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63(11):1092-1096. doi:10.1016/j. biopsych.2007.11.002.
9. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, doubleblind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):654-660. doi:10.4088/JCP.11m07522. Erratum in: J Clin Psychiatry. 2012;73(7):1035.
10. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106-123. doi:10.1080/10550490590924728.
11. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10(12):1691-1715. doi:10.1080/14622200802443569.
12. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994;331(2):123-125. doi:10.1056/NEJM199407143310212.
13. Benowitz NL, Henningfield JE. Reducing the nicotine content to make cigarettes less addictive. Tob Control. 2013;22(suppl 1):i14-7. doi:10.1136/tobaccocontrol-2012-050860.
14. United States Congress. House Committee on Energy and Commerce. Family Smoking Prevention and Tobacco Control Act (H.R. 1256). Washington, DC: U.S. G.P.O.; 2009.
15. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva, Switzerland: World Health Organization; 2003.
16. Ashley DL, Backinger CL, van Bemmel DM, et al. Tobacco regulatory science: research to inform regulatory action at the Food and Drug Administration's Center for Tobacco Products. Nicotine Tob Res. 2014;16(8):1045-1049. doi:10.1093/ntr/ntu038.
17. Kozlowski LT, O'Connor RJ. Cigarette filter ventilation is a defective design because of misleading taste, bigger puffs, and blocked vents. Tob Control. 2002;11(suppl 1):I40-50. doi:10.1136/tc.11.suppl_1.i40.
18. Hatsukami DK, Benowitz NL, Donny E, et al. Nicotine reduction: strategic research plan. Nicotine Tob Res. 2013;15(6):1003-1013. doi:10.1093/ntr/nts214.
19. Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control. 1998;7(4):369-375. doi:10.1136/tc.7.4.369.
20. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005;80(2):259-265. doi:10.1016/j. drugalcdep.2005.04.002.
21. Williams JM, Gandhi KK, Lu S-E, et al. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug Alcohol Depend. 2011;118(2-3):313-319. doi:10.1016/j. drugalcdep.2011.04.009.
22. Strasser AA, Lerman C, Sanborn PM, et al. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend. 2007;86(2-3):294-300. doi:10.1016/j. drugalcdep.2006.06.017.
23. MacQueen DA, Heckman BW, Blank MD, et al. Transient compensatory smoking in response to placebo cigarettes. Psychopharmacology. 2012;223(1):47-54. doi:10.1007/s00213-012-2685-1.
24. Donny EC, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction. 2007;102(2):324-334. doi:10.1111/j.1360-0443.2006.01670.x.
25. Donny EC, Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009;104(1- 2):23-33. doi:10.1016/j.drugalcdep.2009.01.021.
26. Hammond D, O'Connor RJ. Reduced nicotine cigarettes: smoking behavior and biomarkers of exposure among smokers not intending to quit. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2032-2040. doi:10.1158/1055-9965.EPI-13-0957.
27. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reducednicotine standards for cigarettes. N Engl J Med. 2015;373(14):1340-1349 doi:10.1056/NEJMsa1502403.
28. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2013;15(1):121-129. doi:10.1093/ntr/nts098.
29. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV axis-I Disorders-patient edition (SCID-I /P, Version 2.0). New York, NY: Biometric Research Department; 1994.
30. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127. doi:10.1111/j.1360-0443.1991. tb01879.x.
31. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261.
32. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New Jersey, NJ: Lawrence Erlbaum Associates, Publishers; 1988.
33. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2008;10(6):1047-1056. doi:10.1080/14622200802097373.
34. Williams JM, Gandhi KK, Lu SE, et al. Rapid smoking may not be aversive in schizophrenia. Nicotine Tob Res. 2013;15(1):262-266. doi:10.1093/ntr/ntr314.
35. Bridges RB, Combs JG, Humble JW, et al. Puffing topography as a determinant of smoke exposure. Pharmacol Biochem Behav. 1990;37(1):29-39 doi:10.1016/0091-3057(90)90037-I.
36. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42(1):1-5. doi:10.1016/S0006-3223(96)00302-2.
37. Martin LF, Freedman R. Schizophrenia and the alpha-7 nicotinic acetylcholine receptor. Int Rev Neurobio. 2007;78:225-246. doi:10.1016/S0074-7742(06)78008-4.
38. Wing VC, Wass CE, Soh DW, et al. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci. 2012;1248:89-106. doi:10.1111/j.1749-6632.2011.06261.x.
39. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50(2):71-83. doi:10.1016/S0006-3223(01)01134-9.
40. AhnAllen CG, Bidwell LC, Tidey, JW. Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob Res. 2015;17(5):510-514. doi:10.1093/ntr/ntu163.
41. Rose JE, Levin ED. Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br J Addict. 1991;86(5):605-609. doi:10.1111/j.1360-0443.1991.tb01816.x.
42. Benowitz NL, Hall SM, Stewart S, et al. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2479-2485. doi:10.1158/1055-9965.EPI-07-0393.
43. Cook BL, Wayne GF, Kafali EN, et al. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014;311(2):172-182. doi:10.1001/jama.2013.284985.